| (19) |
 |
|
(11) |
EP 1 224 934 A3 |
| (12) |
EUROPEAN PATENT APPLICATION |
| (88) |
Date of publication A3: |
|
26.03.2003 Bulletin 2003/13 |
| (43) |
Date of publication A2: |
|
24.07.2002 Bulletin 2002/30 |
| (22) |
Date of filing: 06.09.1989 |
|
|
| (84) |
Designated Contracting States: |
|
AT BE CH DE ES FR GB GR IT LI LU NL SE |
| (30) |
Priority: |
06.09.1988 SE 8803110
28.10.1988 SE 8803855
|
| (60) |
Divisional application: |
|
03000516.9 |
|
03000517.7 |
|
03000518.5 |
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
93109514.5 / 0569046 |
|
89850294.3 / 0364417 |
| (71) |
Applicant: Pharmacia AB |
|
112 87 Stockholm (SE) |
|
| (72) |
Inventors: |
|
- Stjernschantz, Johan W.
752 38 Uppsala (SE)
- Resul, Bahram
754 49 Uppsala (SE)
|
| (74) |
Representative: HOFFMANN - EITLE |
|
Patent- und Rechtsanwälte Arabellastrasse 4
81925 München
81925 München (DE) |
|
| |
|
| (54) |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
(57) The present invention relates to the use of a 17-phenyl-18,19,20-trinor derivative
of prostaglandin PGA, PGB, PGD, PGE or PGF, wherein the bond between C13 and C14 is
a single or a double bond and wherein the substituent on C15 is a carbonyl group.
It also relates to a respective opthalmological composition.